VivoSeq
Other

Bariatric Surgery

0

Pipeline Programs

39

Active Trials

3

Companies Involved

Bariatric Surgery is an early-stage landscape with 0 programs across 3 companies. The most active players are Aardvark Therapeutics, Inc., Takeda, AstraZeneca.

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

25/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

6/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

121

clinical trials

Completed51 · 42%
Recruiting28 · 23%
Unknown status23 · 19%
Not yet recruiting6 · 5%
Withdrawn4 · 3%
Terminated3 · 2%
Other6 · 5%

Trial Activity

121 trials

Timing of TAP Blocks in Bariatric Surgery
Recruiting·MMcMaster University·Phase 2·NCT06270147·100 enrolled
2024 Tirzepatide-Bariatric Surgery
Recruiting··Phase 4·NCT06721507·50 enrolled
Bariatric Surgery vs. Semaglutide vs. Tirzepatide
Recruiting··Phase 4·NCT06803888·125 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)